Phenotypes Associated with This Genotype

Genotype
MGI:4999985

• Allelic Composition: Col1a1^{tm3(tetO-GFP/RNAi:Apc)Slowe}/Col1a1⁺; Gt(ROSA)26Sor^{tm1(rtTA*M2)Jae}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129S4/SvJae * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:171191 )

• doxycycline-treated mice with lymphoma exhibit median survival of 7.4 months

skeleton

delayed endochondral bone ossification ( J:171191 )

• at E14.5 and E18.5, mice treated with doxycycline at E8.5 exhibit severely delayed or absent endochondral ossification of multiple skeletal elements (spine, ribs, and limbs) compared with wild-type mice

• mice transiently treated with doxycycline between E8.5 and E12.5 exhibit some reduced bone growth (ribs, spine, and skull) compared with wild-type mice

failure of endochondral bone ossification ( J:171191 )

• at E14.5 and E18.5, mice treated with doxycycline at E8.5 exhibit severely delayed or absent endochondral ossification of multiple skeletal elements (spine, ribs, and limbs) compared with wild-type mice

• mice transiently treated with doxycycline between E8.5 and E12.5 exhibit some reduced bone growth (ribs, spine, and skull) compared with wild-type mice

integument

excessive hair ( J:171191 )

• mice treated with doxycycline for 6 weeks (either initiated at birth or 4 to 6 weeks of age) exhibit excessive hair growth compared with wild-type mice

progressive hair loss ( J:171191 )

• in mice treated with doxycycline beyond 20 weeks

• however, reactivation after 4 weeks by doxycycline withdrawal prevents hair loss

abnormal hair follicle morphology ( J:171191 )

• in mice treated with doxycycline beyond 20 weeks

homeostasis/metabolism

hydrops fetalis ( J:171191 )

• in mice treated with doxycycline at E8.5

• however, mice transiently treated with doxycycline between E8.5 and E12.5 do not exhibit edema

limbs/digits/tail

polydactyly ( J:171191 )

• mice transiently treated with doxycycline between E8.5 and E12.5 exhibit extra digits (total 5 to 9) that are largely unsegmented and duplicated along their length compared with wild-type mice

abnormal forelimb morphology ( J:171191 )

• mice transiently treated with doxycycline between E8.5 and E12.5 exhibit severely stunted hind- and forelimb development compared with wild-type mice

abnormal hindlimb morphology ( J:171191 )

• mice transiently treated with doxycycline between E8.5 and E12.5 exhibit severely stunted hind- and forelimb development compared with wild-type mice

growth/size/body

short snout ( J:171191 )

• in mice treated with doxycycline 1 to 2 days prior to birth

• reactivation after 4 weeks of doxycycline treatment does not rescue stunted snout

decreased body size ( J:171191 )

• runting in mice treated with doxycycline 1 to 2 days prior to birth

postnatal growth retardation ( J:171191 )

• in mice treated with doxycycline 1 to 2 days prior to birth

fetal growth retardation ( J:171191 )

• at E14.5 and E18.5 in mice treated with doxycycline at E8.5

neoplasm

increased leukemia incidence ( J:171191 )

• in mice treated with doxycycline from 4 to 6 weeks of age

increased lymphoma incidence ( J:171191 )

• in the thymus and lymph nodes of mice treated with doxycycline from 4 to 6 weeks of age

increased T cell derived lymphoma incidence ( J:171191 )

• in mice treated with doxycycline from 4 to 6 weeks of age

craniofacial

short snout ( J:171191 )

• in mice treated with doxycycline 1 to 2 days prior to birth

• reactivation after 4 weeks of doxycycline treatment does not rescue stunted snout

endocrine/exocrine glands

increased T cell derived lymphoma incidence ( J:171191 )

• in mice treated with doxycycline from 4 to 6 weeks of age